Pharmafile Logo

News and Press Releases

Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER-ILD, in progressive pulmonary fibrosis

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 versus...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 10, 2025

Boehringer Ingelheim
Binger Strasse 173 55216 Ingelheim am Rhein

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds

7 February 2025 -- Bagsværd, Denmark -- Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 7, 2025

Novo Nordisk
abmo@novonordisk.com
Novo Nordisk A/S Novo Allé, 2880 Bagsvaerd Denmark

Novel Findings Using the Parsortix System Demonstrating Role of CTC:B Cell Clusters in Driving Cancer Progression

Findings may enable the development of novel drugs to target B cell and CTC cluster interactions to suppress cancer metastasis This pivotal work is likely to stimulate further interest in...

Category: Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025

ANGLE plc
2 Occam Court, Occam Road, Surrey Research Park, Guilford, GU2 7QB

BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project

The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025

BioMed X
info@bio.mx
BioMed X GmbH Im Neuenheimer Feld 515 69120 Heidelberg

Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies

Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. The treatment with bexicaserin demonstrated favorable safety and...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025

Lundbeck
Iveco House Station Road Watford Hertfordshire WD17 1ET

Phesi announces AI-driven Trial Accelerator platform hits new milestone with data from 132 million patients

Latest version of Trial Accelerator™ incorporates new AI capabilities and product features to unlock a patient-centric approach to trial design and implementation 29 January 2025 -- Boston, US -- Phesi,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025

Phesi
info@phesi.com
East Lyme, Connecticut, US

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

30 January 2025 -- Espoo, Finland -- Orion Corporation and Invenra Inc, an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into...

Category: Drug Discovery, Other, Pharmaceutical
Posted: January 30, 2025

Orion
Orion Corporation Orionintie 1A, FI-02200 Espoo P.O.Box 65, FI-02101 Espoo

Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors

OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple inhibitor of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 30, 2025

Owkin
https://www.owkin.com/
14/16 Bd Poissonnière, 75009 Paris

Image Analysis Group Announces Release of DYNAMIKA V.7, their Award-Winning Cloud Platform for Clinical Trial Imaging 

DYNAMIKA V.7 has achieved the British Standards Institute (BSI) surveillance audit certification following a recent SOC II Type I compliance certification 29 January 2025 -- London, UK -- Image Analysis...

Category: Clinical Trials, Drug Discovery, Other
Posted: January 29, 2025

Image Analysis Group (IAG)
contact@ia-grp.com
2-6 Boundary Row London SE1 8HP

NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform

Findings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sample ANGLE invited to present data at EACR-Illumina webinar on 6 February...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 29, 2025

ANGLE plc
2 Occam Court, Occam Road, Surrey Research Park, Guilford, GU2 7QB

Medable Reports 80% Revenue Growth from Portfolio-Level eCOA Adoption, Sharp Increase Compared to Study-by-Study Adoption

Growing industry confidence drives shift in digital strategy for clinical trial sponsors 28 January 2025 -- California, US -- Medable Inc., a leading provider of clinical development technology, today announced 80%...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 28, 2025

Medable
media@medable.com
525 University Ave Suite A70 Palo Alto, CA 94301

WCG Launches ClinSphere™ Total Enrollment: An All-New Participant Recruitment and Retention SaaS Solution for Clinical Trials

27 January 2025 -- New Jersey, US -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the launch of ClinSphere™ Total Enrollment. This...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 28, 2025

WCG Clinical
info@wcgclinical.com
212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

Protas launches novel unified clinical trial management platform, Cantata

27 January 2025 -- London, UK -- Protas, a not-for-profit organisation transforming the design and delivery of large clinical trials, announces the launch of its unified clinical trial management platform,...

Category: Clinical Trials, Drug Discovery, Other
Posted: January 27, 2025

Protas

Clinigen Announces Strategic Partnership with Tepsivo

Expanding Client Choice with AI-Powered Pharmacovigilance Solutions 27 January 2025 -- London, UK -- Clinigen, the global specialist pharmaceutical services company, today announced a strategic partnership with Tepsivo, a pioneering...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 27, 2025

Clinigen
25 Bedford Square Bloomsbury London WC1B 3HH

Pfizer’s BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with investigator’s choice of...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 25, 2025

Pfizer
235 East 42nd Street NY, NY 10017